<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25196" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Mitomycin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sinawe</surname>
            <given-names>Hadeer</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Casadesus</surname>
            <given-names>Damian</given-names>
          </name>
          <aff>Jackson Memorial Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hadeer Sinawe declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Damian Casadesus declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25196.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Mitomycin is a medication used in the treatment of anal carcinoma, bladder carcinoma, breast carcinoma, head and neck malignancies, and some other gastrointestinal carcinomas. It is in the antineoplastic antibiotic class of medications. This activity reviews the mechanism of action, adverse event profile, indication, and contraindication for mitomycin as a valuable agent in managing gastrointestinal and urogenital cancers.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of mitomycin.</p></list-item><list-item><p>Describe the contraindications of mitomycin.</p></list-item><list-item><p>Review the adverse effects/toxicity of mitomycin.</p></list-item><list-item><p>Outline some interprofessional team strategies for improving care coordination and communication to advance mitomycin and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25196&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25196">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25196.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Mitomycin is an antibiotic medication approved by the Food and Drug Administration (FDA) for use&#x000a0;in the systemic therapy of&#x000a0;metastatic&#x000a0;adenocarcinoma of the stomach or pancreas in combination with other drugs.<xref ref-type="bibr" rid="article-25196.r1">[1]</xref>&#x000a0;Mitomycin is also indicated for the treatment of bladder cancer, with maintenance doses of mitomycin proving effective for decreasing the tumor recurrence rate of low and intermediate-risk tumors.<xref ref-type="bibr" rid="article-25196.r2">[2]</xref></p>
        <p>This medication is also indicated as a potential palliative treatment, especially when other treatments have failed. It also has approval for use as an adjunct to ab-externo glaucoma surgery.<xref ref-type="bibr" rid="article-25196.r3">[3]</xref>&#x000a0;Due to raised intraocular pressure in the development of glaucoma, mitomycin is used during surgery to reduce postoperative scarring following a trabeculectomy or glaucoma drainage surgery.<xref ref-type="bibr" rid="article-25196.r4">[4]</xref><xref ref-type="bibr" rid="article-25196.r3">[3]</xref>&#x000a0;However, its use in hepatic artery chemoembolization is yet to be approved by the FDA.</p>
      </sec>
      <sec id="article-25196.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Mitomycin is an antibiotic that is isolated from the broth of <italic toggle="yes">Streptomyces caespitosus. </italic>This drug has demonstrated antitumor activity.<xref ref-type="bibr" rid="article-25196.r5">[5]</xref><xref ref-type="bibr" rid="article-25196.r6">[6]</xref>&#x000a0;Mitomycin belongs to a group of&#x000a0;alkylating agents that work by&#x000a0;cross-linking the complementary strands found in DNA with absolute specificity and high efficiency for the CpG sequence.<xref ref-type="bibr" rid="article-25196.r3">[3]</xref>&#x000a0;</p>
        <p>Once activated by a reduction cascade, a series of spontaneous transformations cause mitomycin to attack DNA twice, resulting in cross-linking of strands of DNA double helix, thereby inhibiting DNA synthesis. Mitomycin is non-specific for a particular cell cycle phase but can exert its&#x000a0;maximum effect in both the late G as well as the early S-phases.<xref ref-type="bibr" rid="article-25196.r6">[6]</xref></p>
        <p>It also suppresses RNA and protein synthesis at higher concentrations, hence being useful against some bacteria, spirochetes, and viruses. Lending to its toxic profile,&#x000a0;mitomycin has a limited role as an antibiotic.<xref ref-type="bibr" rid="article-25196.r6">[6]</xref>&#x000a0;Mitomycin also causes chromosomal breaks, thus leading to shortened strands of DNA, which eventually leads to chromosomal damage; this property renders&#x000a0;mitomycin a potent carcinogen and teratogen.<xref ref-type="bibr" rid="article-25196.r3">[3]</xref></p>
        <p>In glaucoma surgery, the antifibrotic property of mitomycin prevents tissue scarring&#x000a0;when surgeons create a surgical ocular flap to relieve excess fluid buildup.<xref ref-type="bibr" rid="article-25196.r4">[4]</xref></p>
      </sec>
      <sec id="article-25196.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Mitomycin administration is via the intravenous and intravesical routes. Subcutaneous or intramuscular administration is not advised or recommended. Close monitoring&#x000a0;during&#x000a0;intravenous infusions is advised due to the high likelihood of extravasation. Signs of extravasation include poor blood return, pain, and swelling.<xref ref-type="bibr" rid="article-25196.r7">[7]</xref></p>
        <p>Extreme caution is necessary to prevent extravasation as the drug is known to cause irritation, skin ulceration, and cellulitis. Given the cytotoxic nature of mitomycin, precautions and procedures for handling, reconstitution, and disposal require strict adherence. It can be diluted up to a concentration of 40 micrograms per milliliter at room temperature&#x000a0;in 5% dextrose, 0.9% sodium chloride, or sodium lactate injection. These solutions are stable and&#x000a0;should be used within 4 hours, 48 hours, or 24 hours, respectively.</p>
        <p>
<bold>Dosing for Approved Indications</bold>
</p>
        <p>Refractory stomach or pancreatic cancer: 20 mg/m^2/doise IV on the first day of a 42- or 56-day cycle as part of a multi-drug chemotherapy regimen. If the patient has a serum creatinine greater than 1.7, use of this drug should be avoided.</p>
        <p>In ophthalmology, topical administration is the only established route of administration.<xref ref-type="bibr" rid="article-25196.r3">[3]</xref><xref ref-type="bibr" rid="article-25196.r4">[4]</xref></p>
      </sec>
      <sec id="article-25196.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Bone marrow toxicity is the most commonly reported adverse effect, occurring in most patients&#x000a0;treated with mitomycin in one study. It produces cumulative myelosuppression. Thrombocytopenia and possibly leukopenia may occur anytime within the first two months&#x000a0;after beginning therapy,&#x000a0;with an average&#x000a0;duration of one month.<xref ref-type="bibr" rid="article-25196.r8">[8]</xref>&#x000a0;The recovery time after the termination of therapy was&#x000a0;about ten weeks. About 25%&#x000a0;of the leukopenic or thrombocytopenic episodes were permanent and did not return to baseline levels. As these patients are already immunocompromised, extreme caution is necessary to ensure further bone marrow suppression does not contribute to overwhelming subsequent infections.</p>
        <p>Hemolytic uremic syndrome (HUS)&#x000a0;has been observed in patients receiving systemic medication, with an incidence of &#x0003c;15%.<xref ref-type="bibr" rid="article-25196.r1">[1]</xref><bold>&#x000a0;</bold>Patients presented with microangiopathic hemolytic anemia with fragmented red blood cells on peripheral blood smears. Patients with HUS also suffer the common and well-known side effects of the syndrome, including thrombocytopenia (&#x02264;100,000/mm) and renal failure (serum creatinine &#x02265;1.6 mg/dL), which is irreversible. The use of&#x000a0;blood product transfusions has correlated with exacerbation of the HUS symptoms. There is a high mortality rate of&#x000a0;52% associated with this syndrome.<xref ref-type="bibr" rid="article-25196.r9">[9]</xref></p>
        <p>In another study, nausea, fever, vomiting, and anorexia occurred in up to 14% of people taking mitomycin. Alopecia and stomatitis occurred in up to 4% of individuals. Roughly&#x000a0;2% of the patients showed&#x000a0;a statistically significant rise in&#x000a0;creatinine. However, there was no correlation between the dose given or duration of therapy with the degree of renal impairment.<xref ref-type="bibr" rid="article-25196.r10">[10]</xref></p>
        <p>Pulmonary toxicity has been infrequently reported, with patients&#x000a0;presenting with&#x000a0;dyspnea, nonproductive cough, and pulmonary infiltrates on radiologic imaging.<xref ref-type="bibr" rid="article-25196.r11">[11]</xref>&#x000a0;Vinca alkaloids, a common class of chemotherapeutic agents, also showed&#x000a0;severe or life-threatening dyspnea and bronchospasm within minutes to hours of mitomycin administration.<xref ref-type="bibr" rid="article-25196.r10">[10]</xref>&#x000a0;Adult respiratory distress syndrome has also occurred&#x000a0;in patients receiving mitomycin with other medications.<xref ref-type="bibr" rid="article-25196.r12">[12]</xref>&#x000a0;</p>
        <p>The most frequent adverse events&#x000a0;with ocular administration of mitomycin occur locally and include blebitis, hypotony maculopathy, hypotony, endophthalmitis, cataract development, vascular reactions, and corneal reactions.<xref ref-type="bibr" rid="article-25196.r4">[4]</xref></p>
      </sec>
      <sec id="article-25196.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Mitomycin is generally avoided and somewhat contraindicated in patients with a history of reactions&#x000a0;to the drug, whether a hypersensitivity reaction or an idiosyncratic reaction. Its use is&#x000a0;not recommended for patients with a high serum creatinine &#x0003e;1.7 mg/dL or creatinine clearance &#x0003c;30 mL/min. Other contraindications include&#x000a0;coagulopathy, thrombocytopenia, or any bleeding diathesis.<xref ref-type="bibr" rid="article-25196.r8">[8]</xref>&#x000a0;Mitomycin&#x000a0;should be avoided&#x000a0;in patients with severe immunosuppression due to bone marrow suppression, including leukopenia and thrombocytopenia.</p>
      </sec>
      <sec id="article-25196.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients receiving treatment with this medication should&#x000a0;be observed during and after therapy. HUS may occur at any point during therapy, with signs such as anemia, thrombocytopenia, and renal failure,&#x000a0;especially when&#x000a0;patients receive doses exceeding 60 mg. Fragmented red blood cells may also be present on peripheral smear.<xref ref-type="bibr" rid="article-25196.r1">[1]</xref><xref ref-type="bibr" rid="article-25196.r8">[8]</xref></p>
        <p>The use of mitomycin in pregnant women remains unestablished; therefore, it is not recommended from a safety standpoint. Parenterally-administered mitomycin can cause fetal issues if given during pregnancy; it is classified into category D by the FDA. Breastfeeding is not recommended and is to&#x000a0;be discontinued when receiving mitomycin therapy.<xref ref-type="bibr" rid="article-25196.r13">[13]</xref></p>
      </sec>
      <sec id="article-25196.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Pulmonary toxicity is a rare but well-documented adverse effect of mitomycin C. In one trial at the Mayo Clinic, despite pre-medication with the use of corticosteroids, pulmonary toxicity occurred, with changes in diffusing lung capacity of 9 and PaO2 of 49 mm Hg. A significant number of patients who had bronchoscopies had changes noted on pulmonary histology consistent with lung injury.<xref ref-type="bibr" rid="article-25196.r12">[12]</xref></p>
        <p>Despite initial responses to corticosteroids, 40% of patients still experienced progressive pulmonary insufficiency despite very high corticosteroid doses. Attention must focus on the chronic and progressive phase of lung toxicity associated with mitomycin C, as this event is a largely underestimated complication of the treatment regimen.<xref ref-type="bibr" rid="article-25196.r12">[12]</xref><xref ref-type="bibr" rid="article-25196.r14">[14]</xref></p>
      </sec>
      <sec id="article-25196.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Mitomycin use requires a specialized care setting. Management of therapy and potential adverse effects is only possible&#x000a0;with adequate facilities and&#x000a0;a specialized&#x000a0;interprofessional&#x000a0;team.&#x000a0;Myelosuppression may prove&#x000a0;severe and can necessitate&#x000a0;dose reductions. Therefore, mitomycin&#x000a0;requires an experienced healthcare professional who is&#x000a0;knowledgeable in the discipline of chemotherapy. It also requires close cooperation between primary care physicians, oncologists, hematologists, and pharmacists to enhance patient care, improve outcomes and quality of life.&#x000a0;</p>
        <p>Any practitioner who must give an&#x000a0;intravesical treatment requires appropriate training and assessment. This will apply to all MDs, DOs, NPs, and PAs attending to the patient. They should demonstrate a focused understanding of&#x000a0;underlying malignancy,&#x000a0;associated health care concerns, and matters of safety in&#x000a0;the handling of these drugs, as well as demonstrating clinical competence related to the drug. Nurses attending the patient should also have specialty oncology experience. An oncological board-certified pharmacist must also monitor dosing and consult with the rest of the team regarding adverse events and potential alternative therapy. Interprofessional teamwork, collaboration, and communication are crucial to successful mitomycin therapy. [Level 5]</p>
        <p>Both patients and the practitioner must be educated about mitomycin, its administration, and its adverse effects.</p>
      </sec>
      <sec id="article-25196.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25196&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25196">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25196/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25196">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25196.s11">
        <title>References</title>
        <ref id="article-25196.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verweij</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pinedo</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Mitomycin C: mechanism of action, usefulness and limitations.</article-title>
            <source>Anticancer Drugs</source>
            <year>1990</year>
            <month>Oct</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-13</page-range>
            <pub-id pub-id-type="pmid">2131038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25196.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volpe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Racioppi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Agostino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cappa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Filianoti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bassi</surname>
                <given-names>PF</given-names>
              </name>
            </person-group>
            <article-title>Mitomycin C for the treatment of bladder cancer.</article-title>
            <source>Minerva Urol Nefrol</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>62</volume>
            <issue>2</issue>
            <fpage>133</fpage>
            <page-range>133-44</page-range>
            <pub-id pub-id-type="pmid">20562793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25196.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teus</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>de Benito-Llopis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ali&#x000f3;</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Mitomycin C in corneal refractive surgery.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2009</year>
            <season>Jul-Aug</season>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>487</fpage>
            <page-range>487-502</page-range>
            <pub-id pub-id-type="pmid">19539836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25196.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cabourne</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Schlottmann</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Mitomycin C versus 5-Fluorouracil for wound healing in glaucoma surgery.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2015</year>
            <month>Nov</month>
            <day>06</day>
            <volume>2015</volume>
            <issue>11</issue>
            <fpage>CD006259</fpage>
            <pub-id pub-id-type="pmid">26545176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25196.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charpentier</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shuman</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Antibiotics and UV radiation induce competence for natural transformation in Legionella pneumophila.</article-title>
            <source>J Bacteriol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>193</volume>
            <issue>5</issue>
            <fpage>1114</fpage>
            <page-range>1114-21</page-range>
            <pub-id pub-id-type="pmid">21169481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25196.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomasz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Mitomycin C: small, fast and deadly (but very selective).</article-title>
            <source>Chem Biol</source>
            <year>1995</year>
            <month>Sep</month>
            <volume>2</volume>
            <issue>9</issue>
            <fpage>575</fpage>
            <page-range>575-9</page-range>
            <pub-id pub-id-type="pmid">9383461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25196.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Veeratterapillay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Persad</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bach</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG&#x000a0;Shortage.</article-title>
            <source>Curr Urol Rep</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>68</fpage>
            <pub-id pub-id-type="pmid">27492610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25196.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sturm</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weibel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Donat</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Reiss</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gambaryan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Krohne</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stritzker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Szalay</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapy.</article-title>
            <source>J Transl Med</source>
            <year>2012</year>
            <month>Jan</month>
            <day>11</day>
            <volume>10</volume>
            <fpage>9</fpage>
            <pub-id pub-id-type="pmid">22236378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25196.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salvadori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bertoni</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations.</article-title>
            <source>World J Nephrol</source>
            <year>2013</year>
            <month>Aug</month>
            <day>06</day>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>56</fpage>
            <page-range>56-76</page-range>
            <pub-id pub-id-type="pmid">24255888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25196.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Votanopoulos</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fenstermaker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mansfield</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors.</article-title>
            <source>J Am Coll Surg</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>226</volume>
            <issue>4</issue>
            <fpage>434</fpage>
            <page-range>434-443</page-range>
            <pub-id pub-id-type="pmid">29331663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25196.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abel</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kokosis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Blazer</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC.</article-title>
            <source>World J Surg Oncol</source>
            <year>2017</year>
            <month>Feb</month>
            <day>20</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <pub-id pub-id-type="pmid">28219391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25196.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okuno</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Frytak</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Mitomycin lung toxicity. Acute and chronic phases.</article-title>
            <source>Am J Clin Oncol</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>282</fpage>
            <page-range>282-4</page-range>
            <pub-id pub-id-type="pmid">9167754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25196.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sato</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Haga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anazawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kenjo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wada</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Marubashi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gotoh</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Ex vivo Pretreatment of Islets with Mitomycin C: Reduction in Immunogenic Potential of Islets by Suppressing Secretion of Multiple Chemotactic Factors.</article-title>
            <source>Cell Transplant</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>8</issue>
            <fpage>1392</fpage>
            <page-range>1392-1404</page-range>
            <pub-id pub-id-type="pmid">28901184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25196.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Janeiro Pais</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Casas Agudo</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez Garcia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez Dacal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lamas Meil&#x000e1;n</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez Mart&#x000ed;n</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Pulmonary fibrosis and endovesical mitomycin C].</article-title>
            <source>Actas Urol Esp</source>
            <year>2009</year>
            <season>Jul-Aug</season>
            <volume>33</volume>
            <issue>7</issue>
            <fpage>822</fpage>
            <page-range>822-5</page-range>
            <pub-id pub-id-type="pmid">19757670</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
